Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES SOBRO IN CONNECTION WITH ACQUISITION OF ORANGO GROUP
Mandate

VINGE ADVISES SOBRO IN CONNECTION WITH ACQUISITION OF ORANGO GROUP

January 14, 2016

Vinge has advised the investment company, Sobro, which is owned by the Ragnar brothers as well as  Per-Olof Söderberg, Mikael Ludvigson and David Stenlund Sager, in connection with the acquisition of Orango Group AB together with the company’s management and employees. Orango Group is one of Sweden’s leading business systems specialists with an annual turnover of approximately SEK 130 million and the company has demonstrated good profitability since its formation in 2011.

Vinge’s team consisted of partner Johan Winnerblad together with, among others, associates Erik Claesson, Mathilda Persson, Mattias Sköld and Sara Strandberg. 

 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026